Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

National Cancer Institute (NCI)

Status and phase

Completed

Phase 2

Conditions

Pineoblastoma

Recurrent Medulloblastoma

Recurrent Primitive Neuroectodermal Tumor

Refractory Peripheral Primitive Neuroectodermal Tumor

Central Nervous System Neoplasm

Refractory Medulloblastoma

Treatments

Biological: Bevacizumab

Drug: Irinotecan Hydrochloride

Drug: Temozolomide

Study type

Interventional

Funder types

NIH

Identifiers

NCT01217437

CDR0000686608

ACNS0821

U10CA180886 (U.S. NIH Grant/Contract)

11-00909

U10CA098543 (U.S. NIH Grant/Contract)

COG-ACNS0821

NCI-2011-02605 (Registry Identifier)

Details and patient eligibility

About

This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central nervous system (CNS) primitive neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether temozolomide and irinotecan hydrochloride are more effective with or without bevacizumab in treating medulloblastoma or CNS primitive neuroectodermal tumors.

Full description

PRIMARY OBJECTIVES:

l. To compare the overall survival (OS) of subjects receiving the combination of temozolomide and irinotecan with that of subjects receiving temozolomide, irinotecan (irinotecan hydrochloride), and bevacizumab for recurrent medulloblastoma (MB)/primitive neuroectodermal tumor (PNET) of childhood.

SECONDARY OBJECTIVES:

I. To assess the response rate for each treatment arm amongst patients who are enrolled with measurable disease.

II. To determine event-free survival (EFS) for each patient compared across regimens.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive temozolomide orally (PO) and irinotecan hydrochloride IV over 90 minutes on days 1-5.

ARM II: Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.

In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 5 years.

Enrollment

108 patients

Sex

All

Ages

Under 21 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Medulloblastoma or PNET of childhood that has relapsed or become refractory to standard chemotherapy; patients with pineoblastoma are eligible
Patients must have had histologic verification of the malignancy at original diagnosis or at the time of recurrence
Patients must have clear residual disease, defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) OR diffuse leptomeningeal disease OR clear MRI evidence of disease that may not be measurable in two perpendicular diameters
All patients must have a brain MRI with and without gadolinium and a spine MRI with gadolinium performed within 2 weeks prior to study enrollment
Patients must have a Lansky or Karnofsky performance status score of >= 50%, corresponding to Eastern Cooperative Oncology Group (ECOG) categories of 0, 1, or 2 (use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age)
Patients must have a life expectancy of >= 8 weeks
Patients must have experienced at least one and at most two relapses prior to study enrollment; patients with primary refractory disease are eligible
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
- Myelosuppressive chemotherapy: Must not have received within 3 weeks of entry onto this study (6 weeks if prior nitrosourea)
- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent; at least 3 weeks for biologic agents with a long half life, such as antibodies
- External beam radiation therapy (XRT): Must not have received craniospinal radiotherapy within 24 weeks prior to study entry; the tumor designated as "measurable" for protocol purposes must not have received radiation within 12 weeks prior to study entry); focal radiation to areas of symptomatic metastatic disease must not be given within 14 days of study entry
- Stem cell transplant (SCT): For autologous SCT, >= 3 months must have elapsed prior to study entry
- Study specific limitations on prior therapy:
  - Patients must not have previously received bevacizumab, irinotecan, temozolomide or other anti-vascular endothelial growth factor (VEGF) inhibitor
  - Patients must not be taking enzyme-inducing antiepileptic medicines within 1 week of study entry
Patients must have recovered from any surgical procedure before enrolling on this study:
- Patients with a major surgical procedure within 28 days prior to enrollment should be excluded
- Patients with an intermediate surgical procedure within 14 days prior to enrollment should be excluded
- For minor surgical procedures (including Broviac line or infusaport placement), patients should not receive the first planned dose of bevacizumab until the wound is healed and at least 7 days have elapsed
- There should be no anticipation of need for major surgical procedures during the course of the study
  - Examples of major, intermediate, or minor surgical procedures:
    - Major procedures: Major craniotomy for tumor resection; organ resection; bowel wall anastomosis; arteriovenous grafts; exploratory laparotomy; thoracotomy
    - Intermediate procedures: Ventriculoperitoneal (VP)-shunt placement; stereotactic brain biopsy
    - Minor procedures: Incision and drainage of superficial skin abscesses; punch biopsy of skin lesions; superficial skin wound suturing; bone marrow aspirate and/or biopsy; fine needle aspirations; Broviac line or infusaport placement; paracentesis or thoracocentesis
- Please note: Lumbar punctures or placement of peripherally inserted central catheter (PICC) lines are not considered minor procedures and may occur at any time prior to or during therapy
Hypertension must be well controlled (=< 95th percentile for age and height if patient is =< 17 years) on stable doses of medication
Concomitant medications restrictions:
- Growth factor(s): Must not have received within 7 days of entry onto this study
- Steroids: Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 7 days
- Study Specific: Patients must not be currently taking nonsteroidal anti-inflammatory drugs (NSAIDs), clopidrogel, dipyridamole or aspirin therapy > 81 mg/day
Peripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received filgrastim [G-CSF] within the prior 7 days)
Platelet count >= 100,000/uL (transfusion independent)
Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min OR a serum creatinine based on age/gender as follows:
- =< 0.4 mg/dL (for patients aged 1 month to < 6 months)
- =< 0.5 mg/dL (for patients aged 6 months to < 1 year)
- =< 0.6 mg/dL (for patients aged 1 to < 2 years)
- =< 0.8 mg/dL (for patients aged 2 to < 6 years)
- =< 1 mg/dL (for patients aged 6 to < 10 years)
- =< 1.2 mg/dL (for patients aged 10 to < 13 years)
- =< 1.4 mg/dL (for female patients aged >= 13 years)
- =< 1.5 mg/dL (for male patients aged 13 to < 16 years)
- =< 1.7 mg/dL (for male patients aged >= 16 years)
Urine protein should be screened by dipstick analysis; if protein >= 2+ on dipstick, then urine protein creatinine (UPC) ratio should be calculated; if UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg/24 hours for patient enrollment
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) for age
Central nervous system function defined as
- Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
Adequate coagulation defined as
- International normalized ratio (INR)/prothrombin time (PT) =< 1.5 x upper limit of normal

Exclusion criteria

Patients with a serious or non-healing wound, ulcer, or bone fracture are not eligible for this study
Patients must not have a history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study entry
Patients must not have a known bleeding diathesis or coagulopathy
Patients must not have had significant vascular disease (eg, aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study entry
Patients must not have a known thrombophilic condition (i.e. protein S, protein C or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome); testing is not required in patients without thrombophilic history
Patients must not have evidence of new CNS hemorrhage on baseline MRI obtained within 14 days prior to study enrollment
Patients with a history of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months are not eligible
Patients must not have serious and inadequately controlled cardiac arrhythmia
Female patients who are pregnant are not eligible for this study
Female patients who are breastfeeding are not eligible for this study unless they agree not to breastfeed
Female patients of childbearing potential must have a negative pregnancy test
Sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after the completion of bevacizumab therapy
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies